Avantor and VWR: The Discounts Federal Buyers Were Promised

Avantor agreed to pay $5 million in the Avantor VWR settlement to resolve allegations that VWR overcharged federal agencies by failing to honor Most Favored Customer Pricing and discount terms, the Justice Department announced. The government alleged that VWR raised federal prices while leaving its comparison customer’s prices unchanged. If you handled commercial discounts, government price files or refunds, you may know how that difference reached the government’s bill.

VWR International distributes scientific and technical laboratory supplies, including chemicals, glassware, instruments, protective clothing and production supplies. Avantor acquired VWR in 2017. The Justice Department announced the agreements on July 31, 2024, with the False Claims Act allegations covering government purchases from 2008 through 2017.

Most Favored Customer Pricing Was the Bargain

Most Favored Customer Pricing tied VWR’s government prices to those offered to an agreed private-sector customer. Under the contracts described by the Justice Department, federal purchasers were entitled to the same or better prices. The customer selected for that comparison is called the basis-of-award customer.

The alleged failures reached several parts of that bargain. The government said VWR failed to offer the required customer pricing and increased government prices without increasing prices for the comparison customer. It also allegedly withheld the rebates, discounts, incentives and other favorable terms that customer received.

A rebate can change the bargain without changing the price printed on an invoice. That is why the alleged failure to pass through concessions matters alongside the allegation about price increases. The federal buyer’s entitlement included the favorable terms offered to the comparison customer.

The USC Schaeffer Center’s 2020 paper, The Association Between Drug Rebates and List Prices, shows why concessions matter to a price comparison. Its study of branded drugs found that increases in estimated rebates were associated with higher list prices. The gap between list and net prices included manufacturer payments and discounts to wholesalers and pharmacies. VWR’s alleged failure to pass through concessions makes that distinction relevant to its laboratory-supply contracts too.

The Price Reductions the Government Says Never Reached the Buyer

The Justice Department also alleged that VWR failed to report and adjust federal prices to match the comparison customer’s terms. That included reductions or refunds required by the contracts’ price reduction clauses.

Commercial pricing policy mattered too. The government alleged that VWR failed to report changes from the practices or policies disclosed during negotiations and failed to reduce federal prices accordingly. The alleged overcharge could therefore persist after the commercial bargain changed. Taxpayers were paying under a pricing relationship the government said VWR had stopped honoring.

The government alleged that these failures led VWR to knowingly submit false claims for payment.

The GSA, NIH and VA Contracts

The pricing allegations covered four government contracts, reaching several agencies through different purchasing arrangements. The comparison depended on the terms of the contract used for the purchase.

Two were Multiple Award Schedule contracts with the General Services Administration. They allowed federal buyers to purchase VWR goods at discounted prices and carried Most Favored Customer Pricing requirements. Agencies buying under them included the Department of Defense.

The other arrangements were a Blanket Purchase Agreement with the National Institutes of Health and a Federal Supply Schedule contract with the Department of Veterans Affairs. Both contained best-price provisions, and both agencies bought VWR products under their respective contracts.

That spread matters to someone inside a distributor. A commercial customer’s discount can be visible in one part of the business while federal purchases arrive under several agreements. We connect the customer terms to the particular contracts and purchases they affected, so the account of an overcharge follows the money the agency paid.

What Evidence Is Needed to Prove Fraud?

For a government-pricing case like VWR’s, the evidence connects the contract’s pricing promise, the comparison customer’s actual terms, what the agency was charged and what the company knew. We work with insiders to explain where those records diverge and which decisions caused the difference.

The insider’s contribution is the explanation behind those records. Someone who handled a customer concession may know why it never reached the federal pricing team. Someone responsible for contract reporting may know why a required adjustment was left out. Those are the decisions our whistleblower experts examine with you, alongside the purchases they affected.

The Separate DEA Chemical-Compliance Agreement

Avantor separately agreed to pay $325,000 to resolve civil allegations about listed-chemical compliance from 2013 through 2023. It also entered an administrative agreement with the Drug Enforcement Administration imposing additional reporting and compliance obligations. This part of the resolution concerned chemical transactions and their documentation.

Avantor imports, manufactures, distributes and exports chemicals. The reporting rules described in the Justice Department’s announcement concern listed precursor chemicals, which have legitimate uses and can also be used to manufacture controlled substances.

The government alleged that inspections uncovered failures to document correct registration numbers, repackaging under an improper number and exports under the wrong number. It also alleged incomplete information on import and export forms and shipments meeting or exceeding a reporting threshold without the required submission.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In the VWR case, the Justice Department said a former VWR employee would receive approximately $1.1 million from the False Claims Act settlement.

The employee brought the qui tam lawsuit that the pricing settlement resolved. For a whistleblower with knowledge of government overcharges, the connection between the commercial terms and the government’s payments is the starting point for our work together.

Federal Drug-Price Calculations Show Another Route to an Overcharge

VA drug price reporting puts a manufacturer’s calculation at the center of the federal ceiling price for covered drugs. VWR’s case centered on a distributor’s contractual customer comparison. Each can leave federal purchasers paying more than the applicable terms allow.

Sanofi Pasteur’s federal drug-pricing settlement shows why the distinction matters. The company disclosed incorrect ceiling-price calculations for certain drugs from 2007 through 2011. The VA inspector general found that the resulting overcharges reached back to 2002.

There, the investigation followed a calculation and how far back its error went. In VWR’s case, the allegations followed customer prices, concessions and required contract adjustments. The wider drug pricing fraud problem includes false manufacturer-reported numbers. A distributor employee may instead hold the commercial agreement that shows why the government’s contract price should have changed.

You Know Which Customer Got the Better Deal

If you saw discounts withheld from federal buyers or required refunds left unpaid, talk with our whistleblower experts about the pricing decisions you know. We build your case around the commercial terms, the government purchases and the people who understood the difference, bringing in government-contracting whistleblower lawyers who know pricing disputes. We remain your partners throughout the case, keeping the decisions you witnessed and their cost to federal buyers at the center of our work.